埃罗替尼
缺氧(环境)
药物输送
药品
抗药性
药理学
肿瘤缺氧
脂质体
肺癌
体内
材料科学
癌症研究
医学
化学
癌症
氧气
生物
纳米技术
肿瘤科
表皮生长因子受体
内科学
有机化学
放射治疗
生物技术
微生物学
作者
Fengqiao Li,Hao Mei,Yu Gao,Xiaodong Xie,Huifang Nie,Tao Li,Huijuan Zhang,Jia Li
出处
期刊:Biomaterials
[Elsevier]
日期:2017-11-01
卷期号:145: 56-71
被引量:127
标识
DOI:10.1016/j.biomaterials.2017.08.030
摘要
Tumor hypoxia is a common feature of the tumor microenvironment and has been regarded as one of the key factors in driving the emergence of drug resistance in solid tumors. To surmount the hypoxia-associated drug resistance, we fabricated the novel multifunctional liposomal complexes (ACLEP) that could co-deliver oxygen and molecular targeted drug to overcome the hypoxia-induced drug resistance in lung cancer. The ACLEP were fabricated with liposomes anchored with anti-EGFR aptamer-conjugated chitosan to co-administrate erlotinib and PFOB to EGFR-overexpressing non-small-cell lung cancer. Our results showed that the ACLEP possessed desired physicochemistry, good biostability and controlled drug release. The entrapped PFOB in nanoparticle facilitated the uptake of ACLEP in either normoxia or hypoxic condition. Comparing to those nanoparticles loading erlotinib alone, our innovative oxygen/therapeutic co-delivery system showed a promising outcome in fighting against hypoxia-evoked erotinib resistance both in vitro and in vivo. Hence, this work presents a potent drug delivery platform to overcome hypoxia-induced chemotherapy resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI